The design of protocols that properly mimic the real conditions of ischemic stroke patients (i.e., post-treatment with drugs after the diagnosis of stroke) will certainly maximize the possibility of progression of Nrf2 activators from bench to clinical conditions if the aim is to treat (not prevent) ischemic stroke. This evidence concerns the gene NFE2L2 and Stroke.